The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Jaffer A. Ajani

Department of Gastrointestinal Medical Oncology

The University of Texas M. D. Anderson Cancer Center

TX 77030

USA

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, TX 77030, USA. 1998 - 2010
  • The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. 2010
  • M.D. Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Box 426, USA. 2005

References

  1. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. Ajani, J.A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., Vynnychenko, I., Garin, A., Lang, I., Falcon, S. J. Clin. Oncol. (2010) [Pubmed]
  2. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Ajani, J.A., Wang, X., Izzo, J.G., Crane, C.H., Eng, C., Skibber, J.M., Das, P., Rashid, A. Dig. Dis. Sci. (2010) [Pubmed]
  3. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Ajani, J.A., Correa, A.M., Walsh, G.L., Komaki, R., Lee, J.H., Vaporciyan, A.A., Rice, D.C., Yao, J.C., Maru, D.M., Hofstetter, W.L., Phan, A.T., Swisher, S.G. Cancer (2010) [Pubmed]
  4. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Ajani, J.A., Winter, K.A., Gunderson, L.L., Pedersen, J., Benson, A.B., Thomas, C.R., Mayer, R.J., Haddock, M.G., Rich, T.A., Willett, C.G. Cancer (2010) [Pubmed]
  5. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. Ajani, J.A., Winter, K.A., Gunderson, L.L., Pedersen, J., Benson, A.B., Thomas, C.R., Mayer, R.J., Haddock, M.G., Rich, T.A., Willett, C.G. J. Clin. Oncol. (2009) [Pubmed]
  6. Future developments in esophageal cancer research. Ajani, J.A. Gastroenterol. Clin. North Am. (2009) [Pubmed]
  7. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. Ajani, J.A., Winter, K.A., Gunderson, L.L., Pedersen, J., Benson, A.B., Thomas, C.R., Mayer, R.J., Haddock, M.G., Rich, T.A., Willett, C. JAMA (2008) [Pubmed]
  8. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Ajani, J.A. Cancer (2008) [Pubmed]
  9. Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer? Ajani, J.A. Nat. Clin. Pract. Gastroenterol. Hepatol (2008) [Pubmed]
  10. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. Ajani, J.A., Winter, K., Komaki, R., Kelsen, D.P., Minsky, B.D., Liao, Z., Bradley, J., Fromm, M., Hornback, D., Willett, C.G. J. Clin. Oncol. (2008) [Pubmed]
  11. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. Ajani, J.A., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., Awad, L., Van Cutsem, E. J. Clin. Oncol. (2007) [Pubmed]
  12. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. Ajani, J.A., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., Marabotti, C., Van Cutsem, E. J. Clin. Oncol. (2007) [Pubmed]
  13. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Izzo, J.G., Correa, A.M., Wu, T.T., Malhotra, U., Chao, C.K., Luthra, R., Ensor, J., Dekovich, A., Liao, Z., Hittelman, W.N., Aggarwal, B.B., Ajani, J.A. Mol. Cancer Ther. (2006) [Pubmed]
  14. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. Ajani, J.A., Lee, F.C., Singh, D.A., Haller, D.G., Lenz, H.J., Benson, A.B., Yanagihara, R., Phan, A.T., Yao, J.C., Strumberg, D. J. Clin. Oncol. (2006) [Pubmed]
  15. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Ajani, J.A., Randolph Hecht, J., Ho, L., Baker, J., Oortgiesen, M., Eduljee, A., Michaeli, D. Cancer (2006) [Pubmed]
  16. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Ajani, J.A., Safran, H., Bokemeyer, C., Shah, M.A., Lenz, H.J., Van Cutsem, E., Burris, H.A., Lebwohl, D., Mullaney, B. Invest. New. Drugs (2006) [Pubmed]
  17. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Ajani, J. Cancer (2006) [Pubmed]
  18. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Ajani, J.A. Expert. Opin. Pharmacother (2006) [Pubmed]
  19. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. Ajani, J.A., Winter, K., Okawara, G.S., Donohue, J.H., Pisters, P.W., Crane, C.H., Greskovich, J.F., Anne, P.R., Bradley, J.D., Willett, C., Rich, T.A. J. Clin. Oncol. (2006) [Pubmed]
  20. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. Ajani, J.A., Mansfield, P.F., Crane, C.H., Wu, T.T., Lunagomez, S., Lynch, P.M., Janjan, N., Feig, B., Faust, J., Yao, J.C., Nivers, R., Morris, J., Pisters, P.W. J. Clin. Oncol. (2005) [Pubmed]
  21. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. Ajani, J.A., Fodor, M.B., Tjulandin, S.A., Moiseyenko, V.M., Chao, Y., Cabral Filho, S., Majlis, A., Assadourian, S., Van Cutsem, E. J. Clin. Oncol. (2005) [Pubmed]
  22. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Ajani, J.A., Takimoto, C., Becerra, C.R., Silva, A., Baez, L., Cohn, A., Major, P., Kamida, M., Feit, K., De Jager, R. Invest. New. Drugs (2005) [Pubmed]
  23. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. Ajani, J.A., Faust, J., Ikeda, K., Yao, J.C., Anbe, H., Carr, K.L., Houghton, M., Urrea, P. J. Clin. Oncol. (2005) [Pubmed]
  24. Molecular mechanisms in cancer: what should clinicians know?. Ajani, J., Allgood, V. Semin. Oncol. (2005) [Pubmed]
  25. Evolving chemotherapy for advanced gastric cancer. Ajani, J.A. Oncologist (2005) [Pubmed]
  26. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Ajani, J.A., Walsh, G., Komaki, R., Morris, J., Swisher, S.G., Putnam, J.B., Lynch, P.M., Wu, T.T., Smythe, R., Vaporciyan, A., Faust, J., Cohen, D.S., Nivers, R., Roth, J.A. Cancer (2004) [Pubmed]
  27. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. Ajani, J.A., Mansfield, P.F., Janjan, N., Morris, J., Pisters, P.W., Lynch, P.M., Feig, B., Myerson, R., Nivers, R., Cohen, D.S., Gunderson, L.L. J. Clin. Oncol. (2004) [Pubmed]
  28. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. Ajani, J.A. Oncology (Williston Park, N.Y.) (2003) [Pubmed]
  29. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Ajani, J.A., Faust, J., Yao, J., Komaki, R., Stevens, C., Swisher, S., Putnam, J.B., Vaporciyan, A., Smythe, R., Walsh, G., Rice, D., Roth, J. Oncology (Williston Park, N.Y.) (2003) [Pubmed]
  30. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Ajani, J.A., Baker, J., Pisters, P.W., Ho, L., Mansfield, P.F., Feig, B.W., Charnsangavej, C. Cancer (2002) [Pubmed]
  31. Docetaxel for gastric and esophageal carcinomas. Ajani, J.A. Oncology (Williston Park, N.Y.) (2002) [Pubmed]
  32. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Ajani, J.A., Baker, J., Pisters, P.W., Ho, L., Mansfield, P.F., Feig, B.W., Charnsangavej, C. Oncology (Williston Park, N.Y.) (2002) [Pubmed]
  33. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Ajani, J.A., Baker, J., Pisters, P.W., Ho, L., Feig, B., Mansfield, P.F. Oncology (Williston Park, N.Y.) (2001) [Pubmed]
  34. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Ajani, J.A., Komaki, R., Putnam, J.B., Walsh, G., Nesbitt, J., Pisters, P.W., Lynch, P.M., Vaporciyan, A., Smythe, R., Lahoti, S., Raijman, I., Swisher, S., Martin, F.D., Roth, J.A. Cancer (2001) [Pubmed]
  35. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. Ajani, J.A., Mansfield, P.F., Lynch, P.M., Pisters, P.W., Feig, B., Dumas, P., Evans, D.B., Raijman, I., Hargraves, K., Curley, S., Ota, D.M. J. Clin. Oncol. (1999) [Pubmed]
  36. Recent developments in oral chemotherapy options for gastric carcinoma. Ajani, J.A., Takiuchi, H. Drugs (1999) [Pubmed]
  37. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. Ajani, J.A., Pazdur, R., Dumas, P., Fairweather, J. Invest. New. Drugs (1998) [Pubmed]
 
WikiGenes - Universities